Chemistry:Amenamevir

Short description: Chemical compound

Amenamevir

Clinical data
Trade names	Amenalief
Other names	ASP-2151, ASP2151
ATC code	J05AX26 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N-(2,6-Dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
CAS Number	841301-32-4
PubChem CID	11397521
DrugBank	11701
ChemSpider	9572421
UNII	94X46KW4AE
KEGG	D10564
Chemical and physical data
Formula	C24H26N4O5S
Molar mass	482.56 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1
InChI InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29) Key:MNHNIVNAFBSLLX-UHFFFAOYSA-N

Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).

It acts as an inhibitor of the zoster virus's helicase–primase complex. Amenamevir was approved in Japan for the treatment of shingles in 2017.